Activity of secukinumab, an anti-IL-17A antibody, on brain lesions in RRMS: results from a randomized, proof-of-concept study
Crossref DOI link: https://doi.org/10.1007/s00415-016-8128-x
Published Online: 2016-05-03
Published Print: 2016-07
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Havrdová, Eva
Belova, Anna
Goloborodko, Alla
Tisserant, Anne
Wright, Andrew
Wallstroem, Erik
Garren, Hideki
Maguire, Ralph Paul
Johns, Donald R.
Funding for this research was provided by:
Novartis Pharma AG
Text and Data Mining valid from 2016-05-03